ClinicalTrials.gg

TargetBeta

GIPR

gastric inhibitory polypeptide receptor · Glucagon receptor family

11 programs in company-led studies act on GIPR, from 9 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
TirzepatideruleEli Lillyphase 47220 runningGLP1RChEMBL
UBT251The United Laboratories Internationalphase 31212 runningGCGR, GLP1Ra judged reading
retatrutideruleEli Lillyphase 33311 runningGCGR, GLP1RChEMBL
olatorepatideHansoh Pharmaceutical Groupphase 3127 runningGLP1Ra judged reading
enicepatideHoffmann-La Rochephase 3107 runningGLP1Ra judged reading
VK2735ruleViking Therapeuticsphase 385 runningGLP1Rthe studies' text
BI 3034701Boehringer Ingelheimphase 264 runningGLP1R, NPY2Rthe company's pipeline
HRS-4729Jiangsu HengRui Medicinephase 254 runningGCGR, GLP1Rthe company's pipeline
NNC0519-0130Novo Nordiskphase 2111 runningGLP1Ra judged reading
GIPR Agonist LY3537021Eli Lillyphase 231 running–the company's pipeline
NA-931ruleBiomed Industriesphase 231 runningGLP1R, IGF1the studies' text

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.